BMY Capital expenditure
Capital expenditure at Bristol Myers Squibb rose to $1.3B in fiscal 2025, the highest in the 5 years reported, from $1.2B in 2024.
Payments to acquire property, plant and equipment (or the industry equivalent tag), shown as a positive outflow.
SOURCE: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · EDGAR CompanyFacts · CIK 14272 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Capital expenditure | Change |
|---|---|---|
| FY2025 | $1.3B | +$63M |
| FY2024 | $1.2B | +$39M |
| FY2023 | $1.2B | +$91M |
| FY2022 | $1.1B | +$145M |
| FY2021 | $973M | — |
More SAME DATA, OTHER VIEWS
Capital expenditure across coverage → · BMY company view →
Revenue · Net income · Operating cash flow · Free cash flow · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.